THE DEADLINE IS TODAY - TUESDAY 10 NOVEMBER - for commenting on this decision by NICE, please can you all do your utmost to comment and urge NICE to approve Ruxolitinib for patients with MF. Thank you.
NICE (The National Institute for Health and Care Excellence) is in the process of deciding whether to approve ruxolitinib for patients with MF (myelofibrosis). A draft of the decision is available via nice.org.uk/guidance/indeve...
A team has been involved from MPN Voice and our concerns are that at present it seems ruxolitinib may only be approved for high risk patients. We have concerns about this since the approved indication is for spleen reduction and symptoms regardless of disease stage. The clinical trials have shown that patients with intermediate risk disease benefit in these aspects but also importantly gain years of life with this drug.
This decision is based upon cost not upon effectiveness of ruxolitinib which NICE agrees with.
This is your opportunity to comment on this via this link:
You will need to register for a NICE account in order to contribute your comments - this is an easy process, when you have clicked on the above link you just need to click on the Sign In button and follow the instructions to create your account or sign in if you already have an account.
Clinicians and nurses will do the same but the voice of patients and their families is a very important one.
Please do so by 10th November.